PFE VS ABBV Stock Comparison
Performance
PFE10/100
10/100
PFE returned -36.05% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.
ABBV100/100
100/100
ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
PFE63/100
63/100
22 analysts offer 12-month price targets for PFE. Together, they have an average target of 60.44, the most optimistic target put PFE at 141.39 within 12-months and the most pessimistic has PFE at 44.
ABBV68/100
68/100
20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.
Sentiment
PFE70/100
70/100
PFE had a bullish sentiment score of 69.84% across Twitter and StockTwits over the last 12 months. It had an average of 317.89 posts, 5,792.02 comments, and 19,827.59 likes per day.
ABBV71/100
71/100
ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.
Technicals
PFE11/100
11/100
PFE receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
ABBV11/100
11/100
ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
PFE74/100
74/100
PFE has missed earnings 2 times in the last 20 quarters.
ABBV100/100
100/100
ABBV has missed earnings 0 times in the last 20 quarters.
Profit
PFE68/100
68/100
Out of the last 20 quarters, PFE has had 17 profitable quarters and has increased their profits year over year on 8 of them.
ABBV80/100
80/100
Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.
Volatility
PFE43/100
43/100
PFE has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
ABBV47/100
47/100
ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Dividend
PFE97/100
97/100
PFE's most recent dividend was $0.32 per share, based on a share price of $30.11. It was a payout ratio of 48.46% compared to their total earnings.
ABBV100/100
100/100
ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Pfizer Inc. Summary
New York Stock Exchange / PFE
Healthcare
Drug Manufacturers - General
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
ABBVIE INC. Summary
New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PFE to other companies in the same or a similar industry.